19 September 2013 
EMA/CHMP/569575/2013 
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Kineret 
anakinra 
On 19 September 2013, the Committee for Medicinal Products for Human Use (CHMP) adopted a 
positive opinion for an extension application for the Marketing Authorisation for the medicinal product 
Kineret to add a new strength 100mg/0.67 ml solution for injection in a pre-filled syringe for a new 
indication in adult and paediatric patients for the treatment of Cryopyrin-Associated Periodic 
Syndromes (CAPS). The prefilled syringe also allows the administration of the approved dosage 
required in patients with Rheumatoid Arthritis. The marketing authorisation holder for this medicinal 
product is Swedish Orphan Biovitrum AB (publ). They may request a re-examination of the CHMP 
opinion, provided that they notify the European Medicines Agency in writing of their intention within 15 
days of receipt of the opinion. 
The approved indications for this new strength are as follows: 
Kineret is indicated for the treatment of the signs and symptoms of rheumatoid arthritis in combination 
with methotrexate, in adults with an inadequate response to methotrexate alone. 
Kineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body 
weight of 10 kg or above for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), 
including: 
•  Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, 
Cutaneous, Articular Syndrome (CINCA) 
•  Muckle-Wells Syndrome (MWS) 
• 
Familial Cold Autoinflammatory Syndrome (FCAS) 
Detailed conditions for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after the variation to the 
marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 
within 44 days (Type II variations) and 67 days (Annex II applications) from adoption of the opinion. 
7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom 
Telephone  +44 (0)20 7418 8400  Facsimile +44 (0)20 7418 8613 
E-mail info@ema.europa.eu  Website www.ema.europa.eu 
An agency of the European Union   
© European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. 
 
 
  
 
 
 
                                                
